Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.50 (0.70%)
Bid:
71.20
Ask:
74.00
Spread: 2.80 (3.933%)
Market Cap: £684.32m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

Director/PCA Shareholding

2 Sep 2025 09:30

RNS Number : 6449X
Dr. Martens PLC
02 September 2025
 

Dr. Martens plc (the 'Company')

Notification of Transactions by a Director and Person Closely Associated

The Company announces that it has been notified of the following transactions in the Company's Ordinary 1p shares (the 'shares') undertaken by a director / person discharging managerial responsibility ('PDMR') and a person closely associated with them ('PCA'):

On 1 September 2025, Giles Wilson, Chief Financial Officer, purchased 105,838 shares in his ISA at a price of £0.91377 per share, having sold 105,785 shares at a price of £0.8965 per share.On 1 September 2025, Katie Wilson, a PCA of Giles Wilson, purchased 30,019 shares in her ISA at a price of £0.911447 per share, having sold 30,000 shares at a price of £0.910823 per share.

Following these transactions, which entail the movement of holdings into ISAs, Giles's overall beneficial interest in the Company's shares is 260,193 Ordinary Shares.

The relevant notifications, set out below, are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Giles Wilson

2

Reason for the notification

a)

Position/status

PDMR (Chief Financial Officer)

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Dr. Martens plc

b)

LEI

213800QPT8YM6NQZPH28

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of GBP 0.01

ISIN: GB00BL6NGV24

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.91377

105,838

d)

Aggregated information

 

-

Aggregated volume

-

Price

 

 

 

 

N/A - single transaction

e)

Date of the transaction

1 September 2025

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Giles Wilson

2

Reason for the notification

a)

Position/status

PDMR (Chief Financial Officer)

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Dr. Martens plc

b)

LEI

213800QPT8YM6NQZPH28

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of GBP 0.01

ISIN: GB00BL6NGV24

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.8965

105,785

d)

Aggregated information

 

-

Aggregated volume

-

Price

 

 

 

 

N/A - single transaction

e)

Date of the transaction

1 September 2025

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Katie Wilson

2

Reason for the notification

a)

Position/status

Person Closely Associated with Giles Wilson,

Chief Financial Officer and PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Dr. Martens plc

b)

LEI

213800QPT8YM6NQZPH28

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of GBP 0.01

ISIN: GB00BL6NGV24

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.911447

30,019

d)

Aggregated information

 

-

Aggregated volume

-

Price

 

 

 

 

N/A - single transaction

e)

Date of the transaction

1 September 2025

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Katie Wilson

2

Reason for the notification

a)

Position/status

Person Closely Associated with Giles Wilson,

Chief Financial Officer and PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Dr. Martens plc

b)

LEI

213800QPT8YM6NQZPH28

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of GBP 0.01

ISIN: GB00BL6NGV24

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.910823

30,000

d)

Aggregated information

 

-

Aggregated volume

-

Price

 

 

 

 

N/A - single transaction

e)

Date of the transaction

1 September 2025

f)

Place of the transaction

London Stock Exchange (XLON)

 

For further information, please contact:Paul Rolling, Head of Secretariat+447584243562

Bethany Barnes, Director of Investor Relations+447825187465

ENDS

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. "Docs" or "DMs" were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned "1460" boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. Further information can be found at https://www.drmartensplc.com/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHLTMPTMTTMMJA
Date   Source Headline
8th Jun 202612:26 pmRNSHolding(s) in Company
5th Jun 202610:43 amRNSAdmission to Trading
2nd Jun 20269:00 amRNSDirector/PDMR Shareholding
2nd Jun 20269:00 amRNSAnnual Financial Report
2nd Jun 20268:22 amRNSTotal Voting Rights
27th May 20267:00 amRNSDirectorate change
19th May 20267:00 amRNSEBT Share Purchase
19th May 20267:00 amRNSFY26 Results
14th May 20268:53 amRNSDirector/PDMR Shareholding
1st May 20267:00 amRNSHolding(s) in Company
30th Apr 20268:31 amRNSTotal Voting Rights
29th Apr 20267:00 amRNSHolding(s) in Company
16th Apr 20267:00 amRNSDirector/PDMR Shareholding
15th Apr 20269:50 amRNSDirector/PDMR Shareholding
10th Apr 20261:46 pmRNSDirector/PDMR Shareholding
8th Apr 20267:00 amRNS-RAppointment of Market General Managers
31st Mar 20269:53 amRNSTotal Voting Rights
20th Mar 20267:00 amRNSHolding(s) in Company
13th Mar 20262:03 pmRNSDirector/PDMR Shareholding
27th Feb 202611:04 amRNSTotal Voting Rights
13th Feb 202610:49 amRNSDirector/PDMR Shareholding
30th Jan 202611:15 amRNSTotal Voting Rights
29th Jan 20267:00 amRNSEBT Share Purchase
27th Jan 20267:00 amRNSHolding(s) in Company
27th Jan 20267:00 amRNSQ3 FY26 Trading Statement
15th Jan 20269:24 amRNSDirector/PDMR Shareholding
31st Dec 202511:11 amRNSTotal Voting Rights
31st Dec 202511:11 amRNSTotal Voting Rights
12th Dec 20253:00 pmRNSDirector/PDMR Shareholding
12th Dec 20257:00 amRNSDirector/PDMR Shareholding
8th Dec 20257:00 amRNSDirector/PDMR Shareholding
1st Dec 202512:35 pmRNSBlock listing Interim Review
28th Nov 202511:58 amRNSTotal Voting Rights
25th Nov 20257:00 amRNSHolding(s) in Company
20th Nov 20257:00 amRNSH1 FY26 Results
12th Nov 20252:13 pmRNSDirector/PDMR Shareholding
31st Oct 20252:37 pmRNSTotal Voting Rights
21st Oct 20256:16 pmRNSHolding(s) in Company
20th Oct 20254:06 pmRNSHolding(s) in Company
16th Oct 20252:12 pmRNSDirector/PDMR Shareholding
14th Oct 202511:51 amRNSDirector/PDMR Shareholding
10th Oct 20257:00 amRNSAppointment of joint corporate broker
9th Oct 20251:53 pmRNSDirector/PDMR Shareholding
2nd Oct 20254:20 pmRNSTotal Voting Rights
2nd Oct 20257:00 amRNS-RUAE distribution partnership and LATAM expansion
16th Sep 202511:55 amRNSDirector/PDMR Shareholding
16th Sep 20257:00 amRNSHolding(s) in Company
2nd Sep 20259:30 amRNSDirector/PCA Shareholding
29th Aug 20254:22 pmRNSTotal Voting Rights
12th Aug 20253:17 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.